Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.

• Status: Not yet recruiting
• Trial end date: 2022-07-11
• Target enrollment: 0
• Participant gender: All

Summary

Safety and efficacy of DWRX2003 combination with Remdesivir in moderate to severe COVID-19 patients will be confirmed.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.

Criteria

Inclusion Criteria:

• Age ≥ 18 years at time of signing the Informed Consent Form (ICF).

• SARS-CoV-2 infection documented by RT-PCR within 7 days prior to randomization.

• Hospitalized patients who meet the criteria of moderate or severe COVID-19.

Exclusion Criteria:

• Patients with BMI ≥30.

• Patients receiving or who have received antiviral therapy and antiretroviral therapy within 28 days prior to the screening visit.

• Patients who cannot be administered intramuscularly to bilateral ventro-gluteal area.